Your browser doesn't support javascript.
loading
Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression.
Hu, Qingsong; Ye, Youqiong; Chan, Li-Chuan; Li, Yajuan; Liang, Ke; Lin, Aifu; Egranov, Sergey D; Zhang, Yaohua; Xia, Weiya; Gong, Jing; Pan, Yinghong; Chatterjee, Sujash S; Yao, Jun; Evans, Kurt W; Nguyen, Tina K; Park, Peter K; Liu, Jiewei; Coarfa, Cristian; Donepudi, Sri Ramya; Putluri, Vasanta; Putluri, Nagireddy; Sreekumar, Arun; Ambati, Chandrashekar R; Hawke, David H; Marks, Jeffrey R; Gunaratne, Preethi H; Caudle, Abigail S; Sahin, Aysegul A; Hortobagyi, Gabriel N; Meric-Bernstam, Funda; Chen, Lieping; Yu, Dihua; Hung, Mien-Chie; Curran, Michael A; Han, Leng; Lin, Chunru; Yang, Liuqing.
Afiliación
  • Hu Q; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ye Y; Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston McGovern Medical School, Houston, TX, USA.
  • Chan LC; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Li Y; The Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Liang K; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lin A; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Egranov SD; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhang Y; College of Life Sciences, Zhejiang University, Hangzhou, China.
  • Xia W; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gong J; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Pan Y; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Chatterjee SS; Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston McGovern Medical School, Houston, TX, USA.
  • Yao J; Department of Biochemistry and Biology, University of Houston, Houston, TX, USA.
  • Evans KW; UPMC Genome Center, Pittsburgh, PA, USA.
  • Nguyen TK; Department of Biochemistry and Biology, University of Houston, Houston, TX, USA.
  • Park PK; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Liu J; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Coarfa C; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Donepudi SR; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Putluri V; Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston McGovern Medical School, Houston, TX, USA.
  • Putluri N; Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX, USA.
  • Sreekumar A; Dan L. Duncan Cancer Center, Advanced Technology Core, Alkek Center for Molecular Discovery, Baylor College of Medicine, Houston, TX, USA.
  • Ambati CR; Dan L. Duncan Cancer Center, Advanced Technology Core, Alkek Center for Molecular Discovery, Baylor College of Medicine, Houston, TX, USA.
  • Hawke DH; Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX, USA.
  • Marks JR; Dan L. Duncan Cancer Center, Advanced Technology Core, Alkek Center for Molecular Discovery, Baylor College of Medicine, Houston, TX, USA.
  • Gunaratne PH; Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX, USA.
  • Caudle AS; Dan L. Duncan Cancer Center, Advanced Technology Core, Alkek Center for Molecular Discovery, Baylor College of Medicine, Houston, TX, USA.
  • Sahin AA; Dan L. Duncan Cancer Center, Advanced Technology Core, Alkek Center for Molecular Discovery, Baylor College of Medicine, Houston, TX, USA.
  • Hortobagyi GN; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Meric-Bernstam F; Department of Surgery, Division of Surgical Science, Duke University, School of Medicine, Durham, NC, USA.
  • Chen L; Department of Biochemistry and Biology, University of Houston, Houston, TX, USA.
  • Yu D; Department of Molecular and Cell Biology, Baylor College of Medicine, Houston, TX, USA.
  • Hung MC; Department of Breast Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Curran MA; Department of Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Han L; Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lin C; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yang L; Department of Breast Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nat Immunol ; 20(7): 835-851, 2019 07.
Article en En | MEDLINE | ID: mdl-31160797
ABSTRACT
How tumor cells genetically lose antigenicity and evade immune checkpoints remains largely elusive. We report that tissue-specific expression of the human long noncoding RNA LINK-A in mouse mammary glands initiates metastatic mammary gland tumors, which phenotypically resemble human triple-negative breast cancer (TNBC). LINK-A expression facilitated crosstalk between phosphatidylinositol-(3,4,5)-trisphosphate and inhibitory G-protein-coupled receptor (GPCR) pathways, attenuating protein kinase A-mediated phosphorylation of the E3 ubiquitin ligase TRIM71. Consequently, LINK-A expression enhanced K48-polyubiquitination-mediated degradation of the antigen peptide-loading complex (PLC) and intrinsic tumor suppressors Rb and p53. Treatment with LINK-A locked nucleic acids or GPCR antagonists stabilized the PLC components, Rb and p53, and sensitized mammary gland tumors to immune checkpoint blockers. Patients with programmed ccll death protein-1(PD-1) blockade-resistant TNBC exhibited elevated LINK-A levels and downregulated PLC components. Hence we demonstrate lncRNA-dependent downregulation of antigenicity and intrinsic tumor suppression, which provides the basis for developing combinational immunotherapy treatment regimens and early TNBC prevention.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Oncogenes / Regulación Neoplásica de la Expresión Génica / Presentación de Antígeno / Escape del Tumor / ARN Largo no Codificante / Neoplasias Límite: Animals / Humans Idioma: En Revista: Nat Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Oncogenes / Regulación Neoplásica de la Expresión Génica / Presentación de Antígeno / Escape del Tumor / ARN Largo no Codificante / Neoplasias Límite: Animals / Humans Idioma: En Revista: Nat Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos